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ABSTRACT
Tumor Necrosis Factor alpha antagonists (anti-TNFα) have been extensively used for Crohn’s
disease (CD) treatment. Even though they may control CD symptoms initially, treatment
response varies among patients, which seems to depend on single nucleotide polymorphisms
(SNPs) in TNFα receptors superfamily 1A and 1B (TNFRSF1A/B). Most importantly, M.
tuberculosis infection has been strongly associated with these medications, but no studies have
elucidated the effects of anti-TNFα on CD associated with MAP (Mycobacterium avium
subspecies paratuberculosis; a possible causative agent of CD, and closely related to M.
tuberculosis).
Here, we are investigating the effects of recombinant inflammatory cytokines and anti-TNFα
therapeutics on macrophages infected with MAP isolated from CD patient. We also tested the
prevalence of MAP and the significance of nine SNPs in TNFα, TNFRSF1A and TNFRSF1B
from the blood of 54 CD and 50 healthy subjects by IS900 nPCR.
Both PEGylated and non-PEGylated forms of anti-TNFα increased MAP viability by nearly 1.5
Log CFU/mL, while rIL-6 and rIL-12 induced MAP viability at 5.42 ± 0.25 and 4.79 ± 0.14 Log
CFU/mL, respectively. In contrast, rTNFα reduced MAP survival in infected macrophages by
2.63 Log CFU/mL. Expression of TNFα, IL-6, and IL-12 was upregulated by 3 folds following
MAP or M. tuberculosis infection compared to other bacterial strains (P<0.05).
Four SNPs (TNFα:rs1800629, TNFRSF1A:rs767455, TNFRSF1B:rs1061624 and
TNFRSF1B:rs3397) were overrepresented significantly (P<0.05) among CD patients compared
to healthy controls. The TNFRSF1A:rs767455 GG genotype was found in 15/54 CD patients
(28%), while it was only found in 2/50 healthy controls (4%) [OR = 9.2, 95% CI: 1.98-42.83].
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The TNFRSF1B:rs3397 TT genotype was found in 15/54 CD patients (28%) compared to (4/50)
healthy controls (8%) [OR = 4.4, 95% CI: 1.36-14.14]. Furthermore, the SNPs
TNFRSF1A:rs767455 and TNFRSF1B:rs3397 were associated with downregulating their
corresponding genes significantly (P<0.05). MAP infection was predominantly found among CD
patients in comparison to healthy controls (57% vs 8%, respectively), which was also dependent
on the SNPs TNFRSF1A:rs767455 and TNFRSF1B:rs3397. Our SNP haplotype analysis of
TNFRSF1A:rs767455 and TNFRSF1B:rs3397 indicates that the G – T haplotype is significantly
distributed among CD patients (46%) and MAP infection susceptibility is also associated with
this specific haplotype (31%).
The data indicate that MAP positive CD patients receiving anti-TNFα could result in favorable
conditions for MAP infection, which explains the poor response of many CD patients to this
treatment, leading to adverse outcomes ultimately.
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CHAPTER ONE: INTRODUCTION
Note: This section has been published in part and the citation links are:
Qasem, A., Naser, A. E., & Naser, S. A. (2017). The alternate effects of anti-TNFα therapeutics
and their role in mycobacterial granulomatous infection in Crohn’s disease. Expert review of
anti-infective therapy, 15(7), 637-643.
Cao, B. L., Qasem, A., Sharp, R. C., Abdelli, L. S., & Naser, S. A. (2018). Systematic review
and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with
tumor necrosis factor-α inhibitors (Anti-TNFα). World journal of gastroenterology, 24(25),
2764-2775.
Overview of Crohn’s Disease (CD)
Crohn’s disease (CD) is a chronic relapsing form of inflammatory bowel disease (IBD) affecting
the digestive tract. Patients diagnosed with this disease are suffering from abdominal pain,
persistent diarrhea, and malnutrition. The prevalence of CD has been rapidly increasing in North
America and other countries adapting western lifestyle over the recent decades [1]. Studies
involved human genetics, animal models and clinical trials, have indicated new insights into CD
pathogenesis [2]. We propose and support the hypothesis that dysregulated immune response
against microbial environmental triggers in genetically susceptible subjects lead to development
of CD [Figure 1]. Among the most debated and accepted microbial triggers in CD pathogenesis
is Mycobacterium avium subspecies paratuberculosis (MAP) [3,4,5]. However, current standard
treatment guidelines for CD do not primarily include anti-mycobacterial therapy. The ultimate
goal is to suppress the abnormal inflammatory immune response by using several antiinflammatory drugs and biologics, none of which have any meaningful effect to eradication of
microbial triggers such as MAP. In some circumstances, CD patients might be prescribed with
combinational therapy which includes a biologic and an immunomodulator. As with all therapy,
there are many reported adverse effects of CD medications, especially those related to multiple
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infections [6]. It is also essential to maintain a good nutritional status since CD patients have
reduced ability to absorb proteins, carbohydrates, fat, water, vitamins and minerals.

Therapeutic Context of Targeting Cytokines in CD and Mycobacterial Infection
Contradicting Role of Cytokines in Mycobacterial Infection
Over-reactive immune response in CD patients includes significant elevation in Tumor Necrosis
Factor alpha (TNFa). In normal state TNFa is produced by numerous cells, including
macrophages, CD4+ and CD8+ T-cells, B-cells, neutrophils, endothelial cells, natural killer cells,
smooth muscle cells, fibroblasts and osteoclasts, where its concentration is undetectable
(<10fg/ml) [7]. In CD, macrophages secret high level of TNFa (>200 pg/ml) [8, 9] which causes
upregulation in IFNγ, IL-6, IL-8, IL-1β and granulocyte-macrophage colony stimulating factors,
leading to cell recruitment and formation and maintenance of granuloma [10]. [Figure 2]. The
latter is an alternative approach selected by the immune system to overcome infection by
isolating and neutralizing invasive microorganisms such as MAP [7, 11]. Lower TNFa level
leads to impairment of the immune system in its effort to eradicate infection. Several studies
demonstrated that granulomatous infection has increased significantly in TNFa-deficient animals
[12, 13]. Granulocyte colony stimulating (GM-CSF) may suppress the growth of M. avium and
M. tuberculosis by activating human macrophages [14]. The opposite is true; GM-CSF might
also stimulate the growth of some other intracellular parasites [15]. In vitro studies have also
shown that IL-6 increases the human macrophage susceptibility to M. avium infection which
could explain susceptibility of patients with human immunodeficiency virus (HIV) to
mycobacteria and others [16]. Collectively, cytokines might have bidirectional effect on
intracellular microbial infections, and this could be either by stimulating or suppressing the
2

macrophages activity directly, or it could affect granuloma formation and maintenance leading to
isolation of microbes from the whole system.

Dual Effect of Anti-TNFa and other Immunomodulators in Crohn’s Disease
There are several drugs being prescribed to CD patients which are mainly designed to lower the
TNFa in order to reduce inflammation and achieve remission. Etanercept, infliximab,
adalimumab and certolizumab pegol are just examples of anti-TNFa IgG monoclonal antibodies
which are widely used for treatment of CD patients [11]. Anti-TNFa therapeutic agents indirectly
inhibit the production of IFNγ produced by activated T-cells [17]. A contradicting effect is
expected in cases associated with microorganisms such as MAP, since lowering IFNγ reduces Tcell response, formation of granuloma and isolation of infecting pathogens [18].
Recent in vitro culture studies reported that some drugs used in CD standard treatment have
shown anti-MAP growth activity [19-21]. Altered MAP growth in culture treated with
azathioprine (AZA), 6-mercaptopurine (6-MP), cyclosporine A, tacrolimus and rapamycin has
been reported [19,20]. Methotrexate (MTX) inhibited MAP growth in higher potency than 6-MP
[21]. MTX could potentially affect MAP growth and survival since it reduces folate generation,
which interferes with bacterial DNA replication. MTX in lower doses is also known to
downregulate pro-inflammatory cytokines, which results in clinical improvement in CD patients
[22, 23]. As shown in Table 1, other drugs used in CD standard treatment have contradicting
effect on MAP. Aminosalicylates (5-ASA) intensified MAP growth in culture when the bacteria
were exposed to concentrations higher than 25ug/ml [19]. The negative effect of some of these
drugs on MAP growth suggest that response of CD patients to treatment with AZA, 6-MP,
cyclosporine A, tacrolimus and rapamycin may be due, in part, to the detrimental effect of the
3

drugs on MAP in these patients. On the other hand, the favorable effect of 5-ASA on MAP
growth is alarming to CD patients treated with 5-ASA. However, these in vitro direct effects
might be different from how the drug might interfere with MAP survival under physiological
conditions.
While treatment of CD with anti-inflammatories and biologics is necessary to control
inflammation and to provide short term benefit to the patients, a strategy to eradicate infection in
cases associated with microorganism such as MAP should be included before selection of
treatment. The anti-MAP effect of these non-antibiotics drugs should not be misleading.
Bacteriostatic or bactericidal of any drug requires optimum doses at or above the minimum
inhibitory concentration (MIC) of the drug. Therefore, alternative combined therapy plan should
be considered for long term remission and possibly a cure from this disease. Basically, an
alternative strategy should combine targeted immunotherapy and effective antibiotics where
together they can block the source and the signs of inflammation. Effective antibiotics treatment
includes selection of specific anti-MAP drugs, the necessary treatment duration and enforced
compliance by the patients. RHB-104 is an investigational anti-MAP formulation consisting of
clarithromycin, rifabutin and clofazimine which is currently being used in an FDA-approved
phase III international clinical trial to treat moderate to severe cases of CD [24,25]. It is effective
in vitro against large number of microorganism including several MAP clinical strains, and
others. The ingredients of RHB-104 have demonstrated effective healings in CD patients when
administered individually or in combination with other antibiotics [26,27,28].
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Effects of Immunomodulators on MAP Proteins Immunogenicity
The mycobacterial protein tyrosine phosphatase (PtpA) in MAP shares 90% homology to M.
tuberculosis PtpA [29]. This protein inhibits phagosome-lysosome fusion in human macrophages
by dephosphorylating the vacuolar protein sorting 33B (VPS33B) in the host, also it has shown
efficacy in inhibiting phagosome acidification [30,31]. By this mechanism, the pathogen will be
able to avoid containment lysis in order to establish a successful infection. Recently, the level of
antibodies against PtpA has been found to be significantly elevated in the serum of CD patients
in comparison to healthy subjects [32], and this level was decreased after infliximab treatment
[33]. Xia et al. proposed that PtpA nurtures the survival of MAP inside the host cells as in the
case of M. tuberculosis, and that’s why PtpA antibodies are expected to be higher in CD patients
serum [34]. CD patients treated with AZA showed a significant reduction in PtpA antibodies
level [34]. However, when AZA treatment was combined with other medications such as steroids
or/and 5-ASA this significant reduction was lost, and there was no significant difference in PtpA
antibodies level in patients treated with 5-ASA or steroids alone or in combination [34].

Anti-TNFa Therapeutics Increase Granulomatous Infection
The potential role of anti-TNFa therapeutic agents in developing granulomatous infections varies
among different treatment options. This might be attributed to several factors, such as differences
in their pharmacokinetics. Etanercept for instance has a shorter serum half-life than infliximab or
adalimumab, which results in an extended suppression of TNF following treatment with longer
half-lives TNF antagonists [35]. Studies have shown that the incidence of developing
tuberculosis infection (TB) is higher after using infliximab in comparison to etanercept [36, 37,
38]. Adalimumab is similar to infliximab in its pharmacokinetics, but the incidence of
5

developing TB has been reported to be greater with infliximab use [7]. This could be justified by
differences in the bioavailability and the peak concentration since infliximab is given
intravenously while adalimumab is administered as a subcutaneous injection. Anti-TNFa agents
increased the risk of granulomatous infection, especially M. tuberculosis in a dose dependent
manner [36]. For instance, patients receiving higher dosages of adalimumab (40 mg per week)
have developed active Tuberculosis [39]. Other granulomatous infections are listed in Table 2.

Anti-TNFa Treatment is Linked to Cytotoxicity and Autoimmunity
Cytotoxicity of anti-TNF-a therapeutics
The long-term consequences of anti-TNFa medications and their effects at cellular level needs
further investigation. Infliximab had no effect on THP-1 cells apoptosis in vitro at concentrations
as high as 100ug/ml, however, etanercept and pirfenidone showed a significant reduction in
cellular viability at 0.5 and 300ug/ml, respectively [40].
Treating animal models with monomeric or synthetic dimeric soluble TNF receptors increased
serum TNFa after LPS stimulation in comparison to LPS alone [41]. Grattendick et al. in vitro
study agrees with this result since Etanercept but not Infliximab elevated cell-associated TNFa
up to 6 folds in THP-1 cells following LPS treatment compared to cells treated with LPS alone at
0.1ug/ml [40]. However, the amount of secreted TNFa was neutralized in the same study
following treatment with infliximab and etanercept at 0.1 and 0.01ug/ml, respectively [40].
Pirfenidone is capable of inhibiting TNFa synthesis at the translational level, and it showed
significant reduction of secreted TNFa at 33ug/ml and cell-associated TNFa at 100ug/ml in THP1 cells stimulated by LPS [40, 42].
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Autoimmunity and Anti-TNFa Therapeutics
The immunogenicity of TNF inhibitors is crucial since unintended consequences such as
autoimmunity might occur [43]. Various factors influence the rates of immunogenicity such as
age, gender, genetics, route of administration, drug dose and clearance rate. In clinical trials,
more than 35% of IBD and Rheumatoid arthritis (RA) patients have developed resistance or side
effects to anti-TNFa therapeutic agents due to the development of neutralizing antibodies which
antagonize the therapeutic effects of these medications [43,44]. Since infliximab has been used
for a long time, it is the most extensively studied anti-TNFa therapeutic agent. Infliximab is a
chimeric antibody with 25% murine sequence which makes it more susceptible to induce
immune reactions characterized by secretion of anti-chimeric antibodies known as (HACAs)
[45]. Those antibodies target Infliximab by neutralizing its ability to inhibit TNFa and by
enhancing its clearance due to immune precipitation, which prevents the drug from reaching the
sites of inflammation [46]. HACAs therefore will be able to hinder the clinical efficacy of
infliximab by affecting its pharmacokinetics, pharmacodynamics and the bioavailability [47].
Antibodies against etanercept have been detected in less than 5% of patients receiving this
treatment, however, those antibodies unlike Infliximab antibodies are non-neutralizing [48].
Although adalimumab has a humanized structure, antibodies against it were detected in 12% of
treated patients [49]. Furthermore, patients treated with certulizumab pegol has developed
antibodies against the drug but the clinical aspect remains unknown [45]. Researchers have
evaluated the presence of specific types of antibodies by quantifying IgM and IgG produced
against anti-TNFa therapeutic agents [49]. IgM antibodies were more common in patients treated
with infliximab, etanercept and adalimumab, however the clinical response was not correlated
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with the level of antibodies produced, suggesting that the type of antibody (IgG, IgM or IgA)
plays a significant role in developing adverse reactions or altering the therapeutic effects [50].

Reported Adverse Effects of Anti-TNFa Therapeutics
As previously reported, the most common problem with anti-TNFa therapy is frequent infections
[6]. There is a strong affiliation between mycobacterial infection and anti-TNFa therapeutic
agents, since the risk for developing TB is higher compared to placebo controls [51]. TNFadeficient animal models were more susceptible to develop mycobacterial infections in
comparison to wild-type controls, although they had no difference in survival rate in a healthy
environment [52]. TNFa might have a critical role in the immune defense against mycobacterial
infections, however, the link between blocking TNFa and macrophage mycobactericidal activity
needs further investigation. Indeed, other types of infections have been reported after prescribing
anti-TNFa agents, such as meningitis, sepsis, histoplasmosis and pneumonia [53, 54, 55,58].
Infusion site reactions have been reported after the use of anti-TNFa agents. It could happen at
the infusion time or within one hour of discontinuation, however delayed hypersensitivity
reactions were reported within 3 to 12 days after infusion in CD patients but it was infrequent
[6]. Other reported side effects include malignancy, heart failure, neurologic disorders and
diabetes mellitus in young individuals [6]. Most recently approved humanized monoclonal
antibodies targeting integrins for CD treatment such as vedolizumab has shown lower adverse
effects incidence compared to other traditional Anti-TNFa therapeutics, although natalizumab
carries a significant risk of leukoencephalopathy [63].
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Expert Commentary

Targeting TNF-a has initially shown that antagonizing single cytokine pathway may control the
symptoms of CD or IBD in general in addition to other autoimmune disease such as RA.
However, Anti-TNFa therapy was insufficient to induce response in many CD patients, which
indicates that there are other factors influencing CD pathophysiology. Consequently, Anti-TNFa
therapy could worsen the condition of these particular non-responding patients with inducing
multiple infections especially those affiliated with granuloma maintenance and several unwanted
adverse effects [6]. Studies have reported that about 10 to 30% of IBD patients have shown no
initial response to Anti-TNFa and almost half of the patients who showed an initial response
have lost it over time [59]. Therefore, there is an extensive search for alternative therapeutic
targets such as IL-6, IL-12, and IL-23, in addition to novel inhibition of selective pathways such
as using antisense oligonucleotide to target SMAD-7 and small molecules inhibiting JAK1/JAK-3 pathways [60].
Although many of these investigational medications seem to be promising candidates for
effective treatment of CD, none of them is targeting MAP the hypothesized causative pathogen
of CD except the combinational antibiotic treatment which is currently known as RHB-104
[24,25]. There is an increasing supportive evidence showing the role gut microbiota in CD
pathogenesis [61]. Using antibiotics such as metronidazole in combination with ciprofloxacin
and rifaximin has been recommended for active luminal disease involving the colon in some CD
patients [61]. Furthermore, one meta-analysis has suggested that combining broad spectrum
antibiotics with immunomodulators improves clinical outcome of CD patients [62]. Another
meta-analysis has demonstrated similar efficacy between using immunomodulators or antibiotics
9

in fistulizing CD with lower incidence of severe adverse effects in patients receiving antibiotics
[63]. In contrast, antibiotics might carry a risk for inducing microbial resistance and before using
them for CD treatment, MAP infection must be proven as a strong causative microbial agent
affiliated with CD. In addition to that, CD patients must be informed for drug compliance in
order to avoid antibiotic nonadherence.
For many decades, CD has been widely known as an autoimmune disorder which warranted
treatment with anti-inflammatory and immunosuppressant drugs. Like other autoimmune
disorders, multi-factors have been associated with disease pathogenesis. There is a compelling
evidence pointing to MAP as a major bacterial infectious agent involved in this disease. The
progressive understanding of the immunopathogenesis of CD has opened more avenues into
targeted therapy. However, two issues remain to be addressed:


Screening programs should cover all CD patients in order to detect any persistent
bacterial infection.



Positive status for MAP infection should be eradicated with antibiotics targeting this
pathogen.

It is likely that in the next five years, screening programs will be more efficient to detect MAP
infection in the blood or intestinal tissues of CD patients. Once the patient is diagnosed with
MAP infection, it is highly recommended to start him/her on anti-MAP therapy which is
currently in phase III international clinical trial. Successful treatment of CD with antibiotics
might induce disease remission instead of controlling chronic symptoms with
immunomodulators, especially when combining them with new novel CD therapeutics targeting
other cytokine pathways aside from TNFa.
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Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease
patients treated with TNFα inhibitors
Aims and methods
To perform a meta-analysis on the risk of developing TB infection in CD patients treated with
TNFα inhibitors.
A meta-analysis of randomized, double-blind, placebo-controlled trials of TNFα inhibitors for
treatment of CD in adults was conducted. Arcsine transformation of TB incidence was performed
to estimate risk difference. A novel epidemiologically-based correction (EBC) enabling
inclusions of studies reporting no TB infection cases in placebo and treatment groups was
developed to estimate relative odds.

Results
Twenty-three clinical trial studies were identified, including 5669 patients. Six TB infection
cases were reported across 5 studies, all from patients receiving TNFα inhibitors. Eighteen
studies reported no TB infection cases in placebo and TNFα inhibitor treatment arms. TB
infection risk was significantly increased among patients receiving TNFα inhibitors, with a risk
difference of 0.028 (95%CI: 0.0011-0.055). The odds ratio was 4.85 (95%CI: 1.02-22.99) with
EBC and 5.85 (95%CI: 1.13-30.38) without EBC.
The risk of TB infection is higher among CD patients receiving TNFα inhibitors. Understanding
the immunopathogenesis of CD is crucial, since using TNFα inhibitors in these patients could
favor mycobacterial infections, particularly Mycobacterium avium subspecies paratuberculosis
(MAP), which ultimately could worsen their clinical condition.
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Discussion
One of the most common complications following the use of TNFα inhibitors is increasing
frequency of opportunistic infections [64]. Particularly, there is strong evidence linking
mycobacterial infection to TNFα inhibitors, and TB infection risk is higher among patients
receiving infliximab in comparison to controls [65]. Interestingly, TNFα-deficient animal models
were more susceptible to mycobacterial infections compared to wild-type controls, although there
was no survival rate difference in a healthy environment [66]. This indicates that TNFα plays a
critical role in the immune response against mycobacterial infections.
Several studies have shown that there is a microbial factor affecting CD patients, and MAP was
isolated from intestinal tissues, blood, and milk samples of not only CD patients but also patients
with RA and type 1 diabetes [67, 68]. Since MAP shares molecular homology and activity similar
to TB, inducing TB infection susceptibility is an alarming sign for the immune response against
MAP infection [29, 31].
This study advances knowledge and awareness of the association between TNFα inhibitors and
TB among CD patients. First, a non-biased estimation of TB infection risk associated with TNFα
inhibitors for CD treatment was performed through arcsine transformation of TB incidence, which
enabled the inclusion of all qualified studies including double-zero studies in the analysis. Second,
a novel, epidemiologically-based background correction to adjust for zero counts was developed
to enable the inclusion of double-zero studies into the estimation of the relative effect (odds ratio
in this study). Lastly, with the use of these analytical approaches, a significant increase of TB
infection risk associated with using TNFα inhibitors to treat CD was shown from existing
evidence, challenging findings of previous studies.
In our study, all 23 qualified trials were included. Among these 23 studies, 18 (78%) did not report
12

TB cases from either the anti-TNFα treatment or the control group; these double-zero studies
would have been excluded if we had followed the methods that previous meta-analyses in this area
took. The double-zero observation was not a surprise. TB infection was rare in the Americas,
Europe, Japan, Austria, and South Africa, where these RCTs were conducted. The median sample
size of the control group across these 23 studies was 73 people; the median follow-up duration was
30 wk. Mathematically, only about 0.0084 TB cases would be expected in these control patients if
the background TB infection incidence was 20 cases/100,000 person-years as reported by Aberra
et al[24]. If TNFα inhibitors had increased the TB infection risk by 5 times, there might have been
about a 4% chance to observe 1 TB case in the anti-TNFα treatment arm. Meta-analysis provides
excellent opportunities to pool multiple studies together to improve the estimation of the chance
of observing a TB case. Discarding these double-zero studies (78% of the studies in our analysis)
might decrease the value of meta-analysis.
We regarded the risk difference calculated after arcsine transformation of incidence as the primary
results. The ASD method does not call for any correction for zero counts. Additionally, the
robustness of an ASD estimate is not contingent on the effect size and the treatment-to-control
balance of sample size. These analytical features provided a distinct advantage over either the
Yusuf-Peto method or the Mantel-Haenszel method. However, from a biological perspective, it is
possible that the TB infection risk from the use of TNFα inhibitors in patients with CD may be
better described on a multiplicative scale (relative scale). Thus, a risk difference of 0.028 could be
translated into increasing the risk of TB by a factor of 8, as the number needed to harm was
calculated at 565 patients compared to the background number needed to harm of 5000 patients
(Table 3). However, the 8 times increased risk of TB (based off ASD) only applies if the incidence
of TB remains constant (20 cases/100000 person-years). We thus performed further analysis to
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better describe this multiplicative scale, for which we chose the Yusuf-Peto method because, as
compared to the Mantel-Haenszel method, it can handle single-zero studies [70]. Unfortunately,
the Yusuf-Peto method cannot handle double-zero studies.
We proposed an epidemiologically-based background correction (i.e., EBC) to mathematically
replace zeros. If metrics other than ASD (e.g., odds ratio, hazard ratio or rate ratio) have to be
estimated and the risk of interest is so rare that even one occurrence is not expected, we recommend
that EBC be used for continuity correction instead of adding 0.5 (or a similar number depending
on the ratio of sample size between treatment and control groups) or statistical-model based
estimates [71, 72]. The latter approaches lack biological considerations, and in the case of adding
a number around 0.5, artificially make a much larger background incidence than there actually is
(it would have boosted the background incidence by ~60 times in this meta-analysis).
There are major limitations with the use of EBC. The EBC was based off TB incidence rate in the
UK IBD populations. Although the RCTs in this study were largely conducted in Western
countries, the TB incidence of Crohn’s patients in the UK may not represent the TB incidence of
the countries in which the clinical trials were conducted, let alone the patients who participated in
the clinical trial. Furthermore, the TB incidence rate was found in populations with IBD, which
may not be representative of TB incidence in the population with CD.
Aside from the analytical approach to avoid Simpson’s paradox, the validity to pool results from
individual studies in this meta-analysis largely resides in the fact that each study had a placebotreatment arm. The impact from the difference of study populations was therefore minimized, as
the end point (risk difference or odds ratio) mainly reflected the effect of TNFα inhibitors [the
effect of confounders was either subtracted out (for ASD) or normalized (for ORs)]. Thus,
common factors restricting the use of meta-analysis, such as geographic location, population
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characteristics, exposure, maintenance vs induction trials, status (e.g., phase 3 vs phase 4) of the
clinical trials, secular trend, and TB screening methods could be assumed to be not of major
concern.
Perhaps the fact that only studies in English were included in the analysis may limit the
generalizability of the results, considering that the demographics and trends of CD and TB
infection differ among different regions or different populations [73]. The included studies were
mainly EMA- and FDA-regulated clinical trials conducted in western countries. In fact, only one
study that contained strictly Asian populations was included in this meta-analysis [74]. Thus,
caution should be taken when extrapolating the results from this analysis to predict TB infection
risk of TNFα inhibitors treating CD in non-western countries.
Additional attention should be paid to TB screening. Patients could have had either latent TB
infection that was reactivated or acquired TB infection through exposure. The screening methods
of trials varied and often went unreported. Furthermore, screening out patients based on a positive
tuberculin skin test may have different impacts on the TB infection occurrence due to the different
practices of Bacillus Calmette-Guérin vaccinations [75]. Lastly, two studies did not report
screening methods [76, 77]. Close examination of the additional details of TB screening may
provide further insight on the nature of TB infection – whether it was acquired or reactivated.
We conclude that there is sufficient evidence to assert that using TNFα inhibitors increases the risk
of developing TB infection in patients with CD. Twenty-three studies were analyzed, and multiple
statistical methods repeatedly gave significant risk. To our knowledge, these 23 studies represented
all appropriate literature available for the topic at hand, with an extensive and careful review
conducted. No studies were excluded, provided that they used a placebo control and were
randomized and masked. The randomization minimized potential confounding such as age,
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duration of IBD, and disease activity. These results challenge findings of previous studies, which
reported no significantly increased risk of TB infection when TNFα inhibitors were used to manage
patients with CD [78, 79]. Based on the risk difference found in this study, on average 565 patients
treated with TNFα inhibitors may result in 1 patient getting infected with TB, vs 5000 patients not
treated with TNFα inhibitors producing 1 case of TB, if the background incidence of TB infection
in moderately severe CD is similar to the rates found in the UK IBD population.
The etiology of CD remains uncertain. Evidence suggests that CD may be caused by an immune
response to commensal enteric bacteria [2]. Recent research also suggests that CD is intimately
linked to MAP, which is a TB-like bacterium [3, 25]. The use of TNF inhibitors in these patients
could favor MAP infection and worsen the patient condition. It is currently difficult to come to
conclusions considering that the RCTs did not test for MAP infection – much less reported it.
Further research could be done on looking at patient outcomes and determining which patients had
MAP infection and what their susceptibility to infection was.
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Figures

Figure 1: Interplay of genetics, environmental triggers and immune response in Crohn’s
disease pathogenesis.

Figure 2: Role of TNFα in Crohn’s disease-associated with Mycobacterium avium
subspecies paratuberculosis (MAP) infection
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Tables
Table 1: In vitro effect of immunomodulators on MAP culture.
Drug

6-Mercaptopurine

Mechanism of action

Inhibition of purine

Susceptibility

Minimum concentrations

Reference

S: Sensitive

inhibited MAP growth

R: Resistant

(ug/mL)

S

32.0

18

R

>64.0

18

R

>64.0

18

R

>64.0

18

R

>32.0

18

S

32.0

19

S

64.0

19

S

64.0

19

S

4.0

20

synthesis
5-ASA

Scavenger of free
radicals

Sulfasalazine

Reduces synthesis of
eicosanoids

Sulfapyridine

Inhibition of folic acid
synthesis

Azathioprine

Antagonizing purine
metabolism

Cyclosporine A

Inhibition of
calcineurin

Rapamycin

Inhibition of mTOR
complex

Tacrolimus

Inhibition of
calcineurin
phosphatase

Methotrexate

Inhibition of folic acid
synthesis

Table 2: Other reported causative agents of granulomatous infections after using AntiTNFa therapeutics.
Granulomatous infection causative agent

Reference

Histoplasma capsulatum

56

Listeria monocytogenes

57

Cryptococcus neoformans

35

Coccidioides immitis

35
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CHAPTER TWO: TNFα INHIBITORS EXACERBATE
MYCOBACTERIUM PARATUBERCULOSIS INFECTION IN TISSUE
CULTURE: A RATIONAL FOR POOR RESPONSE OF CROHN’S
DISEASE PATIENTS TO CURRENT APPROVED THERAPY

Note: This chapter has been published in part and the citation link is:
Qasem, A., & Naser, S. A. (2018). TNFα inhibitors exacerbate Mycobacterium paratuberculosis
infection in tissue culture: a rationale for poor response of patients with Crohn’s disease to
current approved therapy. BMJ open gastroenterology, 5(1), e000216.
Introduction
Crohn’s disease (CD) is described as a complex idiopathic inflammation, which can affect any
part of the digestive tract. Patients diagnosed with this chronic form of inflammatory bowel
disease (IBD) suffer from persistent diarrhea, abdominal pain, and malnutrition [1]. The
prevalence of CD in the western countries increased recently, which carries a huge economic
burden on healthcare cost; since 50% of CD patients require surgical intervention within 10 years
of diagnosis [1,2,3].
The etiology of CD involves various components including genetic susceptibility, altered
microbiota and environmental triggers [4]. One of the most investigated pathogens associated
with CD is Mycobacterium avium subspecies paratuberculosis (MAP) [5,6]. However, current
treatment guidelines do not consider this bacterial infection as a source of inflammation.
Although the standard CD therapy has shifted from general immunosuppressants such as
corticosteroids and thiopurines, toward more specific targets including Tumor Necrosis Factor
alpha (TNFα), patients are usually unable to reach full remission or at least maintain a
sustainable clinical response to this kind of therapeutic approach [7,8,9].
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Introducing anti-TNFα biologics (infliximab, adalimumab, certolizumab pegol) to CD treatment
has shown that targeting a specific cytokine could be helpful to control CD symptoms and reduce
flare-ups [7]. Unfortunately, sustainable remission is very limited to a small group of patients
[9]. It has been reported that 10-30% of CD patients, have no initial response to anti-TNFα
therapeautics, and over 50% of initial responders lose their response to treatment over time [10].
Additionally, about 40% of CD patients are at risk of disease relapse after anti-TNFα treatment
discontinuation [11].
Moreover, blocking TNFα carries several adverse effects, including higher risk for malignancy,
heart failure, and multiple infections [4]. There is a well-established evidence supporting the role
of anti-TNFα therapeutics in increasing the incidence for mycobacterial infections including
mycobacterium tuberculosis, which is due to the importance of TNFα in granuloma formation
and containment of M. tuberculosis [12]. Since MAP and M. tuberculosis share molecular
similarities and they both avoid phagosome-lysosome fusion in infected macrophages [13, 14,
15], TNFα remains the essential cytokine required for containment and eradication of MAP. It is,
therefore, alarming for CD patients who are infected with MAP to receive anti-TNFα
therapeutics, and an extensive search for alternative CD therapeutic drug targets is required.
Nevertheless, anti-TNFα treatment might still be considered for CD patients who do not have
MAP infection, and who are genetically more likely to respond to this treatment [16].
For refractory cases of CD, there are a few current medications with a novel therapeutic pathway
known as integrin inhibitors, such as natalizumab (Tysabri®) and vedolizumab (Entyvio®).
Although these two medications have shown a clinical efficacy in CD treatment, however they
increased the risk for Progressive Multifocal Leukoencephalopathy (PML) in multiple clinical
trials [17, 18, 19]. Besides, several pro-inflammatory cytokines are emerging as possible
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therapeutic targets for CD such as IL-6, IL-12, and IL-23 [20]. However, the effect of these
medications on mycobacterial infection is unknown. Additionally, the effect of MAP infection
on upregulating pro-inflammatory cytokines in CD needs further investigation.
In this study, we focused on elucidating the effects of non-PEGylated and PEGylated anti-TNFα
monoclonal antibodies on MAP survival in infected human-derived macrophages. We also
evaluated the ability of recombinant cytokines (TNFα, IL-6, IL-12, IL-23, and IFN-Ƴ) to
modulate MAP survival in vitro. Finally, we evaluated the effects of MAP infection on the gene
expression level of these pro-inflammatory cytokines.

Materials and Methods
Effect of anti-TNFα monoclonal antibodies and recombinant TNFα on MAP in culture
BD Bactec™ MGIT™ Para-TB medium (Sparks, MD) system was used to determine the
bactericidal effects of anti-TNFα therapeutics against clinical MAP strain (UCF4; isolated from
intestinal biopsy of CD patient), and other microorganisms as controls. MGIT-para media with
supplements were used to culture mycobacteria as described previously [21]. For other
microorganisms, nutrient broth media replaced MGIT-para media in MGIT tubes. All tubes
contained a fluorescent molecule embedded in an oxygen sensitive silicone, where fluorescence
is detected in the presence of active respiring bacteria. Anti-TNFα therapeutics were tested in
concentrations between 0 and 200 ug/mL. Recombinant TNFα (rTNFα) was obtained as sterile
filtered lyophilized powder (Gemini®), where each 1.0ug of powder had 2500 Units. A 50ug was
dissolved in 500uL of sterile water in order to prepare 0.1mg/mL stock solution, which was
stored at -20oC. Then, rTNFα was added to bacterial cultures at final concentrations between 0
and 1000U/mL. The microorganisms included in this study are MAP UCF4, Listeria
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monocytogenes ATCC 19112, Klebsiella pneumoniae ATCC 13883, and
Recombinant Escherichia coli. All culture tubes were incubated in BD Bactec™ MGIT™ 320
Analyzer at 37oC. Mycobacterial cultures were read weekly whereas other microorganisms
cultures were read daily. Bacterial growth was visualized under the UV by using Andromeda
BioSens SC 645 UV illuminator.

Effect of anti-TNFα monoclonal antibodies and recombinant TNFα on THP-1 cell viability and
measurement of apoptosis
THP-1 cells (ATCC® TIB-202™) were cultured in RPMI-1640 medium containing 9.8% FBS
(Sigma life science®) and 0.09% BME (Gibco life technologies®), while maintained in a
humidified 5% CO2 incubator at 37oC. Cells were grown until confluency in tissue culture plates
was reached. Then, cells were distributed in 1 mL aliquots in a 24-well tissue culture plate. THP1 cells were then treated with recombinant TNFα or anti-TNFα monoclonal antibodies at final
concentrations between 0 and 50ug/mL, followed by incubation of 24, 48 and 72 hours. Cell
viability was determined by trypan blue exclusion assay. Briefly, 10uL of cell suspension was
mixed with 10uL of 0.4% trypan blue solution. Following five minutes of incubation at room
temperature, 10ul of mixture were injected on a hemocytometer, and the percentage of stained
(viable) cells was counted by binocular microscope. The apoptotic activities of recombinant
TNFα and anti-TNFα monoclonal antibodies were determined by caspase-3 colorimetric assay
(abcam®). At each time point, 500uL of each cell suspension was mixed with 50uL of chilled
lysis buffer and incubated on ice for 10 minutes. Mixture was centrifuged for 1 minute at
10,000g. The cytosolic extract was transferred to another tube and protein concentration was
measured and adjusted to 100ug per 50uL of samples. Caspase reaction mix was prepared by
mixing 50uL of reaction buffer with 0.5uL of 1,4-dithiothreitol (DTT) for each reaction in
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duplicates. Each sample was mixed with 50uL of reaction buffer and 5uL of 4 mM DEVD-p-NA
substrate on a 96-well microplate. Following 90 minutes of incubation at 37oC, the output was
measured at 405nm wavelength by using a microplate reader. Fold increase in caspase-3 activity
was determined by comparing treated samples with the untreated control.

Infection of monocyte-derived macrophages with MAP
THP-1 cells (ATCC® TIB-202™) were cultured as described earlier, then they were
differentiated into monocyte-derived macrophages by adding 50ng/mL of PMA (SigmaAldrich®) for 24 hours of incubation. Monocyte-derived macrophages were then infected with
1x107 bacteria/mL. Microorganisms used include viable M. tuberculosis HR237, MAP UCF4,
and M. smegmatis ATCC 27199, and heat inactivated M. tuberculosis HR237, MAP UCF4, and
M. smegmatis ATCC 27199. Non-mycobacterial microorganisms included L.
monocytogenes ATCC 19112, K. pneumonia ATCC 13883, and Recombinant E. coli. All
microorganisms were used at a final concentration of 1x107 viable bacteria/mL, while maintained
at same conditions for 24 hours.

Measurement of TNFα, IL-6, IL-12, IL-23 and IFN-Ƴ expression in infected macrophages
RNA was isolated from 1.0 mL of each sample suspension post 24 hours of infection, and used
for cDNA synthesis in order to analyze expression of TNFα, IL-6, IL-12, IL-23 and IFN-Ƴ via
RT-PCR. Briefly, cells were centrifuged at 100g for 5 minutes. Pellets were suspended in 1.0 mL
of TRIzol® reagent (Invitrogen) for 15 minutes, and then mixed with 0.2 mL of chloroform.
Following three minutes of incubation at room temperature, samples were then centrifuged at
12,100g for 15 minutes at 4°C. The RNA was transferred from the upper aqueous colorless part
36

into a new 2.0 mL microcentrifuge tube. Each sample was mixed with 0.5 mL of 100%
isopropanol following 10 minutes of incubation at room temperature. Then, each sample was
centrifuged at 12,100g for 10 minutes at 4°C, and mixed with 1.0 mL of 75% ethanol, followed
by centrifugation at 7000g for 5 minutes at 4°C. After RNA pellets were air-dried for 15 min,
samples were suspended in 20ul of RNase free water, and finally heated at 60°C for 10 minutes.
A total amount of 600 ng of each RNA sample was added to 0.2 mL of PCR reaction, 4uL of
iScript™ Reverse Transcription (Bio-Rad®), and up to 20 uL RNase free water for cDNA
synthesis. All samples were transferred to thermal cycler (MyGene™ Series Pelteir Thermal
Cycler), where reaction was performed for 5 minutes at 25°C, 20 minutes at 46°C and 1 minute
at 95°C. A total volume of 1 uL of cDNA (30 ng/uL) was mixed with 10uL of Fast SYBR Green
Mastermix (Thermofisher Scientific®), 1 uL of either IL-6, IL-12, IL-23 or IFN-Ƴ PrimePCR
SYBER Green Assay mix (Bio-Rad®), in addition to 8 uL of molecular biological grade sterile
water in a 96-well microamp RT-PCR reaction plate. The 18s RNA gene oligonucleotide primers
(forward primer: 5’-GTA ACC CGT TGA ACC CCA TT-3’; reverse primer: 5’-CCA TCC AAT
CGG TAG TAG CG-3’) were used as controls to get baseline CT values. The RT-PCR reaction
was performed using 7500 Fast Real-Time PCR System (Applied Biosystems®). Relative mRNA
expression levels were calculated by using the equation (2^ (-∆CT ) x 1000), where ∆CT = Sample
RT-PCR CT value - 18s CT baseline value.

Measurement of TNFα, IL-6, IL-12, IL-23 and IFN-Ƴ protein level in infected macrophages
Following 24 hours of infection with different microorganisms, cells were centrifuged at 100g
for 5 minutes and supernatant was collected. Protein levels were quantified by using ELISA
sandwich assays for TNFα, IL-6, IL-12, IL-23 and IFN-Ƴ (Invitrogen®), according to
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manufacturer’s instructions. Briefly, all samples and reagents were brought up to room
temperature. Six different concentrations of standards were provided and they were added to a
pre-coated plate, in addition to samples and controls (25 μL of each). A volume of 100 μL of
anti-cytokine-horseradish peroxidase enzyme conjugate was added to each well followed by 2
hours of incubation at room temperature. The plate was washed 3 times then 100 μL of
chromogen solution was added into each well, followed by 30 minutes of incubation time at
room temperature. Finally, 100 μL of stop solution was added into each well and absorbance was
read by a plate reader at 450 nm wavelength, then concentrations were calculated from the
generated standard curve equation.

Modulating MAP viability in infected macrophages pulsed with exogenous recombinant
cytokines and anti-TNFα monoclonal antibodies
Recombinant cytokines (rTNFα, rIL-6, rIL-12, rIL-23, and rIFN-Ƴ) were obtained as sterile
filtered lyophilized powders (Gemini®), where each 1.0ug of powder had 2500 Units. 50ug of
each powder was dissolved in 500uL of sterile water in order to prepare 0.1mg/mL stock
solution, which was stored at -20oC. Recombinant cytokines at final concentrations between 0
and 1000U/mL were added to monocyte-derived macrophages infected with MAP strain UCF4.
Similarly, two anti-TNFα monoclonal antibodies (PEGylated and non- PEGylated forms) at final
concentrations between 0 and 50ug/mL were also evaluated. Then, MAP viability was tested
after 24, 48 and 72 hours.

Measurement of bacterial viability in infected macrophages
After infecting monocyte-derived macrophages with MAP for 24 hours, cells were washed to
remove extracellular bacilli, and then recombinant cytokines/anti-TNFα monoclonal antibodies
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were added to the culture accordingly. Monocyte-derived macrophages were collected at three
time points (24, 48 and 72 hours) and lysed with 200uL of M-PER Mammalian reagent
(ThermoScientific) for bacterial viability detection using Live/Dead™ Baclight™
(ThermoFisher Scientific). Briefly, five different proportions of live and dead MAP were
prepared (0:100, 10:90, 50:50, 90:10, 100:0), then 100uL of each bacterial suspension was
pipetted in triplicates into separate wells of 96-well flat-bottom microplate and mixed 100uL of
staining reagent mixture. Following 15 minutes of incubation at room temperature in the dark,
fluorescence intensity was measured at 530nm, which indicates live bacteria reading (green), and
again at 630nm for the dead bacteria reading (red). Data were analyzed by dividing the
fluorescence intensity of the stained bacterial suspensions (Ratio = Emission 1(green)/Emission
2 (red)). The least-squares fit line was generated and the equation was used to calculate the
bacterial viability from the infected cells post-treatment.

Statistical Analysis

Data are expressed as mean ± standard error of the mean by using GraphPad® Prism 7.02
(GraphPad®, CA, USA). Two tailed student’s t-test was used. The difference between
samples and controls was considered statistically significant at a level of *P<0.05.
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Results
Anti-TNFα therapeutics and recombinant TNFα have no direct bactericidal activity against MAP
or other tested microorganisms
In order to rule out the direct bactericidal effects of anti-TNFα monoclonal antibodies and
rTNFα, we tested them in supratherapeutic levels against MAP and non-mycobacterial MGIT
cultures. Both PEGylated and non-PEGylated anti-TNFα monoclonal antibodies have
demonstrated no direct bactericidal activity when they were tested against MAP in addition to 3
non-mycobacteria strains (L. monocytogenes ATCC 19112, K. pneumonia ATCC 13883, and
Recombinant E. coli). All bacterial strains we tested showed resistance to anti-TNFα treatment at
concentrations as high as 200ug/mL (4X Cmax). Similarly, all strains we tested were resistant to
rTNFα treatment at concentrations as high as 1000U/mL. Figure 3 shows the growth florescence
of MGIT tubes incubated with MAP after 14 days of exposure to anti-TNFα, while Figure 4
shows the growth fluorescence of MGIT tubes incubated with non-mycobacteria strains
following 72 hours of anti-TNFα exposure.

Anti-TNFα therapeutics demonstrate similar cytotoxic effects to recombinant TNFα on
uninfected macrophages
To further establish the cytotoxic role of TNFα and anti-TNFα monoclonal antibodies on
monocyte apoptosis and whether these alone are able to modulate monocyte apoptosis
independently of MAP infection, we treated uninfected THP-1 cells with different concentrations
of exogenous rTNFα and therapeutic levels of anti-TNFα antibodies. Following 24 hours of
incubation with 250U/mL of rTNFα, THP-1 cell viability has decreased from 100% to 77.2%,
which continued to decline over time until it reached 63.7% after 72 hours. In a concentrationdependent manner, 500U/mL of rTNFα lead to decrease in THP-1 cell viability from 100% to
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52.6%, while it reached 45.9% with 1000U/mL, following 72 hours of incubation (P<0.05)
[Figure 5A]. Caspase-3 activity has confirmed these findings, since it has shown higher activity
in THP-1 cells treated with rTNFα. At 250U/mL, caspase-3 activity was 2.47 folds higher than
control, while it was 6.49 and 8.92 folds higher in cells treated with 500 and 1000U/mL of
rTNFα following 72 hours of incubation, respectively (P<0.05) [Figure 6A]. Surprisingly, antiTNFα monoclonal antibodies showed similar cytotoxic effects as rTNFα in a dose-dependent
manner. The viability of THP-1 cells treated with 5ug/mL of non-PEGylated anti-TNFα started
to decrease over 72 hours of incubation, when it reached 70.6%. Higher concentrations have
shown further decline in cell viability, when it reached 62.8%, 57% and 48% following 72 hours
of incubation with 10, 20, and 50ug/mL, respectively (P<0.05) [Figure 5B]. The PEGylated form
of anti-TNFα was less cytotoxic, but it still demonstrated decline in THP-1 cell viability
following 72 hours of incubation, when cell viability was 74.7%, 68.8%, 62.6% and 57.9%,
treated with 5, 10, 20, and 50ug/mL, respectively (P<0.05) [Figure 5C]. Similarly, caspase-3
activity was 4.9 and 4.4 folds higher than control following 72 hours of treatment with 50ug/mL
of non-PEGylated and PEGylated anti-TNFα therapeutics, respectively (P<0.05) [Figure 6B and
6C].

MAP induces expression of TNFα, IL-6 and IL-12 in infected macrophages
We have found that MAP and M. tuberculosis induce TNFα expression in infected macrophages
significantly (3.2 ± 0.23 and 2.8 ± 0.13, respectively), compared to M. smegmatis (0.8 ± 0.17)
and other non-mycobacteria species following 24 hours of infection [Figure 7A]. Similarly, we
found that MAP and M. tuberculosis both had about two times higher IL-6 expression (2.9 ±
0.41 and 2.6 ± 0.19, respectively) compared to M. smegmatis (1.3 ± 0.12) or other non41

mycobacterial pathogens (P<0.05). Furthermore, when M. tuberculosis and MAP were both heat
inactivated (80°C for 20 minutes), they have lost their activity to induce IL-6 expression (0.35 ±
0.14 and 0.29 ± 0.11, respectively) (P<0.05) [Figure 7B]. Additionally, IL-12 expression was
also significantly higher in MAP or M. tuberculosis infected macrophages (1.6 ± 0.36 and 1.5 ±
0.29, respectively), but only in comparison to non-mycobacteria species (P<0.05) [Figure 7C].
However, the expression of other pro-inflammatory cytokines (IFN-Ƴ and IL-23) was not
significantly higher in MAP or M. tuberculosis infected macrophages [Figure 7D and 7E].
Similarly, protein level of TNFα, IL-6 and IL-12 was significantly elevated following MAP or
M. tuberculosis infection, in comparison to other bacterial strains [Figure 8].

Recombinant TNFα decreases MAP survival in infected macrophages
First, we tested the effects of adding exogenous rTNFα into MAP infected macrophages at
different concentrations between 0 and 1000U/mL. We found that MAP viability drops with time
significantly in a concentration-dependent manner. At 500U/mL, MAP viability has declined
from 7.0 (Log. CFU/mL) to 3.95 ± 0.22, 3.31 ± 0.34 and 2.11 ± 0.17, following 24, 48, and 72
hours of incubation, respectively (P<0.05) [Figure 9A]. At the maximum concentration we have
tested, adding rTNFα at 1000U/mL to MAP infected macrophages, had decreased MAP viability
from 7.0 (Log. CFU/mL) to 1.50 ± 0.15, following 72 hours of incubation (P<0.05) [Figure 9A].

Anti-TNFα therapeutics increase MAP survival in infected macrophages
In contrast, treating MAP infected macrophages with anti-TNFα monoclonal antibodies,
increases MAP survival in a dose-dependent manner. The non-PEGylated form of anti-TNFα at
50ug/mL, had MAP viability of 5.09 ± 0.11 (Log. CFU/mL), while the untreated control had
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4.02 ± 0.16 (Log. CFU/mL) (P<0.05) [Figure 9B]. Similarly, the PEGylated anti-TNFα had
increased MAP viability up to 5.63 ± 0.14 (Log. CFU/mL) at 50ug/mL following 72 hours of
incubation (P<0.05) [Figure 9C].

Recombinant IL-6 promotes MAP survival in infected macrophages
Since we found that MAP modulates some pro-inflammatory cytokine gene expression in
infected macrophages, it was worthy to test the effects of exogenous recombinant cytokines on
MAP survival. We tested rIL-6 at different concentrations between 0 and 1000U/mL.
Interestingly, rIL-6 has promoted MAP survival significantly in a concentration-dependent
manner. Following 72 hours of incubation, MAP viability was 3.42 ± 0.39, 4.25 ± 0.23, 4.82 ±
0.19 and 5.42 ± 0.25 (Log. CFU/mL), at 0, 250, 500, 1000U/mL of rIL-6, respectively (P<0.05)
[Figure 10A]. Similarly, rIL-12 had some positive effect on MAP viability in infected
macrophages; however, it was only significant at a concentration of 1000U/mL, when MAP
viability was 4.79 ± 0.14 compared to 3.73 ± 0.33 (Log. CFU/mL), following 72 hours of
incubation (P<0.05) [Figure 10B]. On the other hand, both rIL-23 and rIFN-Ƴ had similar effects
to rTNFα, where they had detrimental effects on MAP survival. MAP viability has declined from
7.0 to 2.76 ± 0.16 and 2.95 ± 0.19 (Log. CFU/mL), following 72 hours of incubation with
1000U/mL of rIL-23 and rIFN-Ƴ, respectively [Figure 10C and 10D]. The effects of IL-6
neutralizing receptors (Anti-IL-6) and IL-12 neutralizing receptors (Anti-IL-12) have reduced
MAP viability in concentration dependent manner. Following 72 hours of incubation, MAP
viability was 4.76±0.23, 3.83±0.27 and 3.14±0.17 (Log. CFU/mL), at 0, 20 and 50ug/mL,
respectively (P<0.05) [Figure 10E]. In parallel, MAP viability following 72 hours of incubation
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with anti-IL-12 was 5.11±0.27, 4.19±0.14 and 3.49±0.29 (Log. CFU/mL), at 0, 20 and 50ug/mL,
respectively (P<0.05) [Figure 10F].

Discussion
Macrophages exhibit several mechanisms in order to eradicate intracellular pathogens, such as
releasing reactive oxygen intermediates, changing phagolysosomal acidity, and production of
pro-inflammatory cytokines [22]. TNFα is one of those cytokines, which has a prominent role
during mycobacterial infection, resulting in a formation of a complex circuit of other cytokines
able to modulate T-cells and macrophages response to infection and granuloma formation [23].
Consequently, blocking TNFα function in animal models induced mycobacterial proliferation
and reduced granuloma formation, indicating that TNFα is a primary cytokine for protection
against mycobacterial infection [24,25,26]. However, current treatment guidelines for many
inflammatory disorders of supposed non-infectious origin, recommend blocking TNFα pathway
in order to suppress the hyperactive immune response and inflammation [27].
Although there is a strong evidence demonstrating the involvement of MAP in CD, there is no
recommendations of using antibiotics for CD treatment so far [21]. On the contrary, the clinical
use of anti-TNFα therapeutics has increased the risk for multiple infections including
tuberculosis [28, 29, 30]. Thus, assessment of latent tuberculosis infection status is highly
recommended in order to determine if any patient intended to initiate anti-TNFα therapy has a
risk for development of active disease [31].
This study was concerned with identifying the detrimental ability of recombinant TNFα, IL-6,
IL-12, IL-23 and IFN-Ƴ on MAP survival in infected macrophages and if blocking TNFα

44

function by anti-TNFα monoclonal antibodies modulates MAP viability in vitro. Additionally,
our goal was to identify which pro-inflammatory cytokines are highly expressed by macrophages
following MAP infection. A recent study has reported that infliximab treatment increases MAP
viability in infected macrophages from CD patients by predominant induction of MAP dormant
form [32]. Our data shows that both PEGylated and non-PEGylated forms of anti-TNFα
therapeutics do not have any direct bactericidal effects against MAP or other non-mycobacterial
strains at supratherapeutic concentrations (>200mg/mL). However, these medications increased
MAP survival in infected macrophages in a dose-dependent manner, which indicates that CD
patients receiving such treatment are at a higher risk for MAP growth if they had MAP infection
before initiation of therapy. In contrast, MAP viability declined in infected macrophages pulsed
with exogenous rTNFα in a concentration-dependent manner, which shows that TNFα plays a
significant role in protection against MAP infection.
Furthermore, anti-TNFα therapeutics demonstrated similar cytotoxicity level to rTNFα at
therapeutic concentrations, which explains why these medications increase the risk for infections
once they induce apoptosis in macrophages. In addition, we measured expression level of TNFα,
IL-6, IL-12, IL-23, and IFN-Ƴ in infected macrophages following 24 hours. We found that TNFα,
IL-6 and IL-12 are also expressed significantly in MAP or M. tuberculosis infected macrophages,
which shows that a high level of these cytokines in CD patients could be a result of MAP
infection. Interestingly, MAP survival was induced significantly when exogenous rIL-6 was
added to infected macrophages in a concentration-dependent manner. However, rIL-23 and IFNƳ had a similar effect to rTNFα, where they reduced MAP viability significantly with higher
concentrations.
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Newly emerging monoclonal antibodies indicated for CD treatment have shifted from targeting
TNFα into more selective targets such as anti-IL-6 (PF-04236921), anti-IL-23 (AMG-139) and
anti-IL-12/IL-23 (ustekinumab) [20]. Indeed, IL-6 is highly expressed in CD patients [33, 34,
35]. Therefore, blocking IL-6 pathway is anticipated to reduce the hyperactive immune response
among CD patients. Moreover, our data suggests that IL-6 promotes MAP survival in infected
macrophages. Thus, targeting this cytokine in specific will lead to decline in MAP viability,
which could replace anti-TNFα treatment eventually. Additionally, in M. tuberculosis infected
macrophages, IL-6 was found to inhibit IFN-Ƴ responsive genes at the transcriptional level
selectively, which also results in inhibition of MHC class II induction [36]. Clinical studies are
needed to offer a proof of principle for this new CD drug target with dual effect on MAP
infection and inflammation.
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Figures

Figure 3: Direct bactericidal activity of non-PEGylated anti-TNFα (1) and PEGylated antiTNFα (2) therapeutics against MAP growth in MGIT fluorescence system at 200ug/mL,
following 14 days of incubation. (P) Indicates positive control (0ug/mL) and (N) is a
negative control.
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Figure 4: Direct bactericidal activity of non-PEGylated anti-TNFα (A) and PEGylated antiTNFα (B) therapeutics against bacterial growth in MGIT fluorescence system at 200ug/mL,
following 72 hours of incubation. (1): S. aureus, (2): Recombinant E. coli, (3): K.
pneumonia and (4): L. monocytogenes. (P) Indicates positive control (0ug/mL) and (N) is a
negative control.

Figure 5: Cytotoxicity of rTNFα (A), non-PEGylated anti-TNFα (B) and PEGylated antiTNFα (C) therapeutics determined by Trypan blue exclusion assay, following 24, 48 and 72
hours of incubation.

*P<0.05
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Figure 6: Cytotoxicity of rTNFα (A), non-PEGylated anti-TNFα (B) and PEGylated antiTNFα (C) therapeutics determined by Caspase-3 activity assay, following 24, 48 and 72
hours of incubation.
*P<0.05

Figure 7: Expression of TNFα (A), IL-6 (B), IL-12 (C), IL-23 (D) and IFN-Ƴ (E) in
monocyte-derived macrophages following 24 hours of bacterial infection. Bacterial strains
presented in the X-axis are 1: Control (without infection), 2: M. tuberculosis (heat
inactivated), 3: MAP UCF4 (heat inactivated), 4: M. tuberculosis, 5: MAP UCF4, 6: M.
smegmatis, 7:K. pneumonia, 8: L. monocytogenes, 9: Recombinant E. coli.
*P<0.05
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Figure 8: Level of TNFα (A), IL-6 (B), IL-12 (C), IL-23 (D) and IFN-Ƴ (E) in monocytederived macrophages following 24 hours of bacterial infection. Bacterial strains presented
in the X-axis are 1: Control (without infection), 2: M. tuberculosis (heat inactivated), 3:
MAP UCF4 (heat inactivated), 4: M. tuberculosis, 5: MAP UCF4, 6: M. smegmatis, 7:K.
pneumonia, 8: L. monocytogenes, 9: Recombinant E. coli.
*P<0.05

Figure 9: MAP viability in monocyte-derived infected macrophages pulsed with rTNFα
(A), non-PEGylated anti-TNFα (B) and PEGylated anti-TNFα (C) therapeutics, following
24, 48 and 72 hours of infection.
*P<0.05
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Figure 10: MAP viability in monocyte-derived infected macrophages pulsed with IL-6 (A),
IL-12 (B), IL-23 (C), IFN-Ƴ (D), anti-IL-6 and anti-IL12 following 24, 48 and 72 hours of
infection.
*P<0.05
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CHAPTER THREE: GENETIC POLYMORPHISMS IN TUMOR
NECROSIS FACTOR RECEPTORS (TNFRSF1A/1B) ILLUSTRATE
DIFFERENTIAL TREATMENT RESPONSE TO TNFα INHIBITORS IN
PATIENTS WITH CROHN’S DISEASE
Note: This section has been published in part and the citation links are: Qasem, A., Ramesh, S.,
& Naser, S. A. (2019). Genetic polymorphisms in tumour necrosis factor receptors
(TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with
Crohn’s disease. BMJ Open Gastroenterology, 6(1), e000246.
Introduction
Tumor necrosis factor-α (TNFα) is a pro-inflammatory cytokine that has been found to be
dysregulated in numerous inflammatory disorders including rheumatoid arthritis (RA), psoriasis
and Crohn’s disease (CD) [1, 2]. It is secreted primarily by macrophages, but it can also be
produced by lymphocytes, natural killer cells and mast cells [3]. In order to exert its biological
activity, TNFα binds to two different cell-surface receptors; tumor necrosis factor-α receptor
superfamily 1A (TNFRSF1A), which is expressed in most tissues, and tumor necrosis factor-α
receptor superfamily 1B (TNFRSF1B), which is typically found in immune cells [4].
Targeting TNFα by monoclonal antibodies (Anti-TNFα) such as adalimumab (Humira®) and
infliximab (Remicade®) has shown that blocking this cytokine signaling pathway may control the
symptoms of hyperactive immune response in CD initially [5]. However, there is a significant
variable response to anti-TNFα therapeutics among patients receiving this treatment [6].
Additionally, clinical observations have reported that 10-30% of inflammatory bowel disease
(IBD) patients, have no initial response to anti-TNFα treatment, and over 50% of the initial
responders have lost response to treatment over time [7].
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Clinical studies have shown that anti-TNFα therapeutics have many deleterious side effects, such
as malignancy, neurologic disorders, heart failure and more importantly multiple infections [8].
Since TNFα plays a critical role in the immune defense against infections, it was unsurprising to
notice that TNFα-deficient animal models are more susceptible to develop mycobacterial
infections compared to wild-type controls [9]. On the other hand, patients receiving anti-TNFα
treatment are at higher risk for meningitis,
sepsis, histoplasmosis, and pneumonia [10, 11, 12]. Moreover, the risk for tuberculosis
development has substantially increased in patients receiving anti-TNFα, which might raise a
question about their effect on Mycobacterium avium subspecies paratuberculosis (MAP)
infection in a subset of CD patients [13, 14, 15,16]. Thus, prescribing anti-TNFα to CD patients
without considering MAP infection could worsen disease condition eventually.
Genetic polymorphisms are not only associated with the overall risk of developing an
inflammatory disorder, but they also play a role in the treatment outcome. For instance,
polymorphisms in TNFRSF1A and TNFRSF1B have been shown to affect anti-TNFα treatment
response significantly among CD patients [17, 18, 19]. However, the mechanism of those effects
remains unknown. Predicting the efficacy of anti-TNFα treatment based on patient’s genetics and
MAP infection status would be more effective and beneficial to patients by reducing the risk for
adverse effects and treatment cost.
In this study, we investigated the frequency of single nucleotide polymorphisms (SNPs) in
TNFα, TNFRSF1A and TNFRSF1B among CD patients in comparison to healthy controls, in
addition to their effect on gene expression and susceptibility to MAP intracellular infection.
Finally, we further linked the effect of SNPs in these genes and presence of MAP to anti-TNFα
treatment response in CD patients.
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Materials and Methods
Clinical Samples:
Peripheral blood from a total of 104 subjects (54 CD patients and 50 healthy controls) were
included in his study. All participants provided written informed consent prior to enrollment, and
the study was approved by the University of Central Florida Institutional Review Board
#IRB00001138.
Each subject provided two 4.0-mL K2-EDTA coded blood tubes, where one tube was processed
for detection of MAP infection, and the second tube was processed for gene expression analysis
and genotyping of nine SNPs in TNFα, TNFRSF1A and TNFRSF1B. There was no significant
difference in average age or gender between the two groups (CD vs healthy controls). All subject
demographics are listed in Table 3.

Extraction of DNA and Detection of MAP by IS900 Nested PCR:
Purified white blood cells separated from blood samples were cultured in BD Bactec™ MGIT™
Para-TB medium for 6 months of incubation at 37 °C. Mycobacterial growth was measured
initially using the UV illuminator and 1.0 mL was used for DNA extraction and nested PCR
(nPCR) analysis as described earlier [15, 20]. Briefly, MAP infection was detected using MAPspecific IS900 derived oligonucleotide primers. Round one of amplification was performed using
P90 (GTTCGGGGCCGTCGCTTAGG) and P91 (GAGGTCGATCGCCCACGTGA) primers
following these conditions conditions: 95 °C for 5 min, then 34 cycles of 95 °C for 1 min, 58 °C
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for 1.5 min, 72 °C for 1.5 min. Final extension of 10 min at 72 °C. The amplified product from
this round was 398 bp.
A second round of amplification involved using AV1 (ATGTGGTTGCTGTGTTGGATGG) and
AV2 (CCGCCGCAATCAACTCCAG) primers, which was performed following these
conditions: 95 °C for 5 min, then 34 cycles of 95 °C for 1 min, 58 °C for 1.5 min, 72 °C for
1.5 min. Final extension of 10 min at 72 °C. The final product following this round was 298 bp,
which was identified on 2% agarose gel.

Identification of SNPs in TNFα, TNFRSF1A and TNFRSF1B Genes:
Genomic DNA was purified from peripheral blood leukocytes using QIAamp® DNA Blood Mini
Kit (Qiagen™) following manufacturer’s instructions. TaqMan™ genotyping assays (Applied
Biosystems™) for TNFα (rs1800629, rs1799964, and rs1799724), TNFRSF1A (rs4149584,
rs767455, and rs4149570) and TNFRSF1B (rs1061624, rs1061622, and rs3397) were performed
on isolated DNA samples following manufacturer protocol at the University of Florida
Pharmacotherapy and Translational Research Department (Gainesville, FL). Briefly, the reaction
mixture had 2x TaqMan™ master mix and 20x assay working stock (primers with VIC and FAM
fluorophore attachment). Isolated DNA samples along with reaction mixture and controls were
added into a 384-well microtiter plate, following RT-PCR assay (one cycle at 95°C for 10
minutes, 92°C for 15 seconds and 50 cycles at 58°C for 1 minute) using Applied Biosystems™
QuantStudio™ RT-PCR System. The plate was analyzed for VIC and FAM fluorophores for at
551 nm and 517 nm, respectively. Fluorescence of VIC or FAM alone determined that the
sample had allele 1 or allele 2, while VIC and FAM together determined that the sample was
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heterozygous for each allele. Gene mutation, location and phenotype for SNPs used in this study
are summarized in Table 4 [21-27].

Gene Expression of TNFα, TNFRSF1A, and TNFRSF1B by RT-PCR:
RNA was isolated from 1.0 mL of whole blood samples, and used for cDNA synthesis in order
to analyze gene expression of TNFα, TNFRSF1A, and TNFRSF1B via RT-PCR. Briefly, 1.0 mL
of blood was transferred into 2.0 mL RNA-ase free microcentrifuge tube, and then centrifuged at
1000 rpm for 5 minutes. Pellets containing leukocytes were collected and suspended in 1.0 mL
of TRIzol® reagent (Invitrogen) for 15 minutes of gentle shaking. A total volume of 0.2 mL of
chloroform was added to each tube, and the mixture was then incubated at room temperature for
3 min. All tubes were then centrifuged at 11,400 RPMs for 15 minutes at 4°C. The upper
aqueous colorless phase containing RNA was transferred into a new 2.0 mL RNA-ase free
microcentrifuge tubes. A total volume of 0.5 mL of 100% isopropanol was then added following
10 minutes of incubation at room temperature. Each tube was then centrifuged at 11,400 RPMs
for 10 minutes at 4°C. A total volume of 1.0 mL of 75% ethanol was used to wash RNA pellets
and then centrifuged at 8,700 RPMs for 5 minutes at 4°C. RNA pellets were air-dried for 15-30
min, suspended in 20 ul of RNase free H2O, and finally heated at 60°C for 10 minutes.
For cDNA synthesis, 600 ng of RNA from each sample was added to 0.25 mL tubes containing
0.2 mL of PCR reaction, 4 uL of iScript™ Reverse Transcription (Bio-Rad®), and up to 20 uL
RNase free H2O. All tubes were then transferred to thermal cycler (MyGene™ Series Pelteir
Thermal Cycler) and ran for 5 minutes at 25°C, 20 min at 46°C and 1 min at 95°C. The final
concentration of cDNA synthesized for each sample was 30 ng/uL. A total volume of 1 uL of
cDNA was mixed with 10 uL of Fast SYBR Green Mastermix (Thermofisher Scientific®), 1 uL
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of either TNFa, TNFRSF1A, or TNFRSF1B PrimePCR SYBER Green Assay mix (Bio-Rad®)
and 8 uL of molecular biological grade sterile H2O in a 96-well microamp RT-PCR reaction
plate. Controls of 18s RNA gene oligonucleotide primers (forward primer: 5’-GTA ACC CGT
TGA ACC CCA TT-3’; reverse primer: 5’-CCA TCC AAT CGG TAG TAG CG-3’) were used
in order to obtain baseline CT readings. The 7500 Fast Real-Time PCR System (Applied
Biosystems®) was used to perform the RT-PCR reaction. Relative mRNA expression levels
were calculated using the equation (2^ (-∆CT ) x 1000), where ∆CT = Sample RT-PCR CT reading
- 18s CT baseline.

Statistical Analysis:

All statistical tests were performed using GraphPad Prism® 7.02. MAP infection incidence
was used to estimate the power of this study. Since CD patients have MAP infection incidence
proportion of nearly 40%, while in healthy controls MAP infection incidence proportion is
about 10% [13, 14], at 90% power and alpha (Type I error) of 0.05, our calculated sample size
was 84 samples (42 CD and 42 healthy controls). We also aimed for a similar number of
Matsukura’s et al. anti-TNFα treatment response study which included 81 participants [17].
For genotype frequency, we used two-tailed Z test and odd ratio analysis to compare between the
presence of SNPs in CD patients vs. healthy controls. At each locus examined, SNP genotypes
were subcategorized into 4 groups (major, heterozygous, homozygous and both heterozygous +
homozygous), then tested for significance within each subcategory at P<0.05 and a 95%
confidence interval (CI). For haplotype analysis, we used Fisher’s exact test since we had a
smaller number of samples. CD Patients were subcategorized into 4 haplotype groups and then
tested for significance in between MAP infection groups. P-value of less than 0.05 was
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considered significant. For gene expression analysis, first, we compared the average gene
expression in CD vs. healthy control for each gene regardless of their genotype using unpaired
two-tailed t-test at P<0.05 and a 95% confidence interval (CI), then we compared individuals
who carried two major alleles with others for each SNP tested by using one-way ANOVA, where
Newman-Keuls post test was selected for multiple comparisons. For MAP infection
susceptibility, we compared infection proportions between SNP genotypes and major alleles in
CD group and healthy controls separately using two-tailed Z test at P<0.05. Age and gender
were not included as covariates as for all data sets no age or gender effects were observed.

Results
Frequency of SNPs in TNFα, TNFRSF1A, and TNFRSF1B among CD patients
We have assessed 104 subjects (54 CD patients and 50 healthy controls) for three SNPs in TNFα
(rs1800629, rs1799964, and rs1799724), three SNPs in TNFRSF1A (rs4149584, rs767455, and
rs4149570) and three SNPs in TNFRSF1B (rs1061624, rs1061622, and rs3397). Genotype
distribution of these SNPs conveyed the Hardy-Weinberg equilibrium.
We identified one SNP in TNFα (TNFα:rs1800629) with a significant difference in frequency in
CD patients compared to healthy controls (P<0.05). The TNFα:rs1800629 GA genotype was
found in 20/54 CD patients (37%) compared to 7/50 healthy controls (14%) [OR = 3.6, 95% CI:
1.37-9.54]. As shown in Table 5, the other two SNPs (TNFα:rs1799964 and TNFα:rs1799724)
have shown no significance among CD patients compared to healthy controls (P>0.05).
Similarly, there was a significant difference in frequency of one SNP in TNFRSF1A
(TNFRSF1A:rs767455) among CD patients compared to healthy controls (P<0.05). The
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TNFRSF1A:rs767455 GG genotype was found in 15/54 CD patients (28%), while it was only
found in 2/50 healthy controls (4%) [OR = 9.2, 95% CI: 1.98-42.83]. The other two SNPs
(TNFRSF1A:rs4149584 and TNFRSF1A:rs4149570) have shown no significance (P>0.05).
Additionally, two SNPs in TNFRSF1B (TNFRSF1B:rs1061624 and TNFRSF1B:rs3397) were
found to be significant in CD patients compared to healthy controls (P<0.05). The
TNFRSF1B:rs1061624 AG genotype was found in 27/54 CD patients (50%) compared to 15/50
healthy controls (30%) [OR = 2.3, 95% CI: 1.04-5.22]. The TNFRSF1B:rs3397 CT genotype
was found in 31/54 CD patients (57%) compared to (15/50) healthy controls (30%) [OR = 3.1,
95% CI: 1.40-7.07]. Besides, the TNFRSF1B:rs3397 TT genotype was also significantly found
in 15/54 CD patients (28%) compared to (4/50) healthy controls (8%) [OR = 4.4, 95% CI: 1.3614.14]. However, TNFRSF1B:rs1061622 was not found to be significant among CD patients in
comparison to healthy controls (P>0.05). A complete list of SNPs and genotyping frequency is
shown in Table 5.

SNPs Downregulates TNFRSF1A and TNFRSF1B Gene Expression in CD
We quantified relative gene expression level of TNFα, TNFRSF1A, and TNFRSF1B in all 104
study participants. Then, we further analyzed the data according to each SNP present, in order to
find out if SNPs are associated with gene expression level. In general, the relative expression of
TNFα was more than three times higher in CD patients (2.44 ± 0.30), in comparison to healthy
subjects (0.72 ± 0.20), regardless of SNPs involved (P<0.5). However, none of TNFα SNPs

(rs1800629, rs1799964, and rs1799724) was associated with gene expression level significantly
(P >0.05) [Figure 11A, 10B, and 11C].
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Overall, the expression level of TNFRSF1A and TNFRSF1B was significantly downregulated in
CD patients (0.38 ± 0.15; P<0.5 and 0.34 ± 0.13; P<0.05, respectively), compared to healthy
subjects (0.79 ± 0.24 and 0.66 ± 0.17, respectively) [Figure 11D - 10I]. Nevertheless, CD
patients with the SNP TNFRSF1A:rs767455 who had GG genotype, had a significantly lower
relative gene expression level compared to patients without SNP who had AA genotype (0.26 ±
0.09 vs 0.49 ± 0.12; P<0.5) [Figure 11E].
Similarly, the expression level of TNFRSF1B was significantly lower in CD patients with the
SNP TNFRSF1B:rs3397 who had either CT (0.32 ± 0.11) or TT (0.2 ± 0.09) genotype, compared
to patients without SNP (0.59 ± 0.10) who had CC genotype (P<0.5) [Figure 11I].

SNPs in TNFRSF1A and TNFRSF1B Induce Susceptibility to MAP Infection
We evaluated MAP infection status in all 104 study participants by IS900 nPCR analysis, which
is very sensitive and specific for MAP. Overall, 31/54 CD patients were infected with MAP
compared to only 4/50 healthy control [OR = 15.5, 95% CI: 4.88-49.22, P<0.05].
We further looked for any association between a specific genotype in all SNPs we tested and the
presence of MAP infection. Interestingly, CD patients with the SNP TNFRSF1A:rs767455 who
had either AG or GG genotype were more susceptible to MAP infection (63% and 66.6%,
respectively), while CD patients without SNP (AA genotype) were 41% infected with MAP.
However, this result was not statistically significant (P>0.05) [Figure 12A]. On the other hand,
CD patients with the SNP TNFRSF1B:rs3397 who had either CT or TT genotype were
significantly susceptible to MAP infection (58% and 70.5%, respectively), compared to CD
patients without SNP (CC genotype), who were only 17% infected with MAP (P<0.05) [Figure
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12B]. None of the additional SNPs we tested (rs1800629, rs1799964, and rs1799724 of TNFα,
rs4149584 and rs4149570 of TNFRSF1A, rs1061624 and rs1061624 of TNFRSF1B) were found
to be significantly associated with higher susceptibility to MAP infection.

SNP Haplotypes Distribution and MAP Infection Susceptibility
After we have identified TNFRSF1A:rs767455 and TNFRSF1B:rs3397 as SNPs associated with
lower gene expression and higher MAP infection susceptibility in CD patients, we further
performed haplotype analysis of these two SNPs. The haplotype frequencies among CD patients
and healthy controls showed a significant difference for the G – T haplotype (P<0.05), which
was found in 25/54 CD patients (46%), while in healthy controls it was 7/50 (14%) [Figure 13].
Consequently, MAP infection was significantly higher among CD patients who had the G – T
haplotype (17/25), which contributes to 31% of CD patients overall, while none of the healthy
controls had the G – T haplotype and MAP infection at the same time. As described in Table 6,
none of the other SNP haplotypes inferred from TNFRSF1A and TNFRSF1B (A – C, G – C and
A – T) were found to be associated with susceptibility to MAP infection significantly (P>0.05).

Discussion
Increased level of TNFα has been found in the inflamed intestinal mucosa of CD patients, which
is considered an essential mediator of immunologic response for this inflammatory disease [28].
Consequently, TNFα plays a role in increasing intestinal permeability, granuloma formation and
coagulation pathways [3]. Most recently, we elucidated the relationship between MAP infection
and the upregulation of TNFα expression in vitro, which has shown that both MAP and M.
tuberculosis induce gene expression significantly in comparison to other mycobacteria and non-
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mycobacteria strains [29]. Although inhibition of TNFα has shown a positive clinical outcome in
some CD patients, poor response was also found in others, which leaves those patients with
severe side effects and higher susceptibility to infections [13]. Therefore, several
pharmacogenetic studies have evaluated the variation of anti-TNFα treatment response among
CD patients in order to predict treatment response ultimately [17, 18, 19].
Genetic polymorphisms in TNFRSF1A and TNFRSF1B were found to be correlated with antiTNFα treatment response in CD patients. Specifically, the TNFRSF1A:rs767455 AG and GG
genotype has a significant difference in frequency among non-responders to anti-TNFα treatment
compared to the majority of drug responders who had the AA genotype [16]. Similarly, the
TNFRSF1B:rs3397 CT and TT also have a significant difference in frequency among anti-TNFα
non-responders in comparison to CD patients who were classified as drug responders (CC
genotype) [18, 30]. However, these observations were limited to drug response only, while the
molecular effects of these SNPs were not discussed.
Since MAP is a suspected microbial causative agent of CD [14, 15, 31, 32], it was worthy to find
out if genetic polymorphisms are inducing susceptibility to MAP infection in CD patients, which
will ultimately influence anti-TNFα treatment outcome. Therefore, we tested 104 subjects (54
CD patients and 50 healthy controls) for selective SNPs in TNFα (rs1800629, rs1799964, and
rs1799724), TNFRSF1A (rs4149584, rs767455, and rs4149570) and TNFRSF1B (rs1061624,
rs1061622, and rs3397). First, four out of these nine SNPs were found to have a significant
difference in frequency among CD patients compared to healthy controls (TNFα:rs1800629,
TNFRSF1A:rs767455, TNFRSF1B:rs1061624 and TNFRSF1B:rs3397), which also correlates
with previous reports [33, 34, 35]. Secondly, we quantified gene expression level of TNFα,
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TNFRSF1A and TNFRSF1B in all study participants. We found that TNFα relative expression
level is about 3.4 folds higher in CD patients compared to healthy controls overall. However,
none of TNFα-associated SNPs had a significant association with TNFα gene expression level.
The expression of TNFRSF1A and TNFRSF1B was significantly downregulated (~ 2 folds) in
CD patients compared to healthy controls regardless of SNPs involved. Furthermore, the SNPs
TNFRSF1A:rs767455 and TNFRSF1B:rs3397 were both found to be associated with a
significant lower gene expression. Additionally, MAP infection was predominantly found among
CD patients in comparison to healthy controls (57% vs 8%, respectively). Interestingly, MAP
infection was also associated with the SNPs TNFRSF1A:rs767455 and TNFRSF1B:rs3397.
Furthermore, our SNP haplotype analysis of TNFRSF1A:rs767455 and TNFRSF1B:rs3397
indicates that the G – T haplotype has a significant difference in frequency among CD patients
(46%) and MAP infection susceptibility is also associated with this specific haplotype (31%).
It is relevant to compare between MAP and M. tuberculosis infection since mycobacterial protein
tyrosine phosphatase (PtpA) in MAP shares 90% homology to PtpA in M. tuberculosis [36]. This
protein inhibits phagosome–lysosome fusion in the macrophage by dephosphorylating the host
vacuolar protein sorting 33B (VPS33B). Consequently, the pathogen will be able to avoid
containment eradication and it establishes a successful intracellular infection by preventing
fusion of lysosome and phagosome into the phagolysosomal complex [37, 38]. Therefore, the
primary mechanism for MAP eradication is by inducing apoptosis of the infected macrophage
through TNFα dependent mechanism [39, 40]. This is a critical point when we consider antiTNFα treatment for CD patients who are infected with MAP. In addition to genetic testing of
selective SNPs we discussed, MAP infection screening method should be implemented before
initiation of therapy. Finally, in figure 14 we suggest following a treatment algorithm for CD,
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based on patient’s haplotype inferred from TNFRSF1A rs767455 (A/G) and TNFRSF1B rs3397
(C/T).
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Figures

Figure 11: Gene expression level of TNFα, TNFRSF1A and TNFRSF1B according to each
allele type in selected SNPs (A – I) among CD patients (N = 54) and healthy controls (N =
50). Unpaired two-tailed t-test at P<0.05 and a 95% confidence interval (CI) was used to
test gene expression significance in CD patients vs healthy controls, then one-way ANOVA,
where Newman-Keuls post test was selected for multiple comparisons was used to test
individuals who carried two major alleles with others for each SNP.
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Figure 12: Influence of TNFRSF1A (rs767455) and TNFRSF1B (rs3397) SNPs on MAP
infection susceptibility in CD patients (N = 54) and healthy subjects (N=50). Infection
proportions were compared between SNP genotypes and major alleles in CD patients and
healthy controls separately using two-tailed Z test at P<0.05.

Figure 13: Haplotypes inferred from rs767455 (A/G) and rs3397 (C/T), and their
distributions in CD patients (A) and healthy subjects (B).
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Figure 14: Recommended CD treatment algorithm based on haplotypes inferred from
TNFRSF1A rs767455 (A/G) - TNFRSF1B rs3397 (C/T).
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Tables
Table 3: Demographics of Study Participants.
Diagnosis

Number

Age Range

Average Age

Gender Ratio
(Male : Female %)

All Subjects

104

20 - 66

35

53:47

Crohn’s Disease

54

21 - 66

39

48:52

Healthy Controls

50

20 - 63

31

58:42
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Table 4: Gene mutations, locations and mutation phenotypes of SNPs selected for this study.
Gene

Reference SNP

Gene
Mutation*

Location and
AA Change*

Mutation Phenotype

Reference

TNF

rs1800629

G→A

Promoter

Higher susceptibility to CD

22

rs1799964

T→C

Promoter

Associated with IBD in general

23

rs1799724

C→T

Promoter

Linked to ankylosing spondylitis

24

rs4149584

C→T

Exon 4
(R→Q)

Higher susceptibility to MS

25

rs767455

A→G

Exon 1: No
AA change

Used to predict anti-TNFα response in CD

17

rs4149570

G→T

320bp
upstream of
gene

rs1061622

T→G

Exon 6
(M→R)

rs1061624

G→A

Exon 10

rs3397

C→T

Exon 10

TNFRSF1A

TNFRSF1B

Used to predict anti-TNFα response in RA
26

Higher susceptibility to IBD

27

Higher susceptibility to IBD

27

Used to predict anti-TNFα response in CD

18

* Gene mutation and location data were obtained from the National Center for Biotechnology Information (NCBI) [21]

Table 5: Genotype frequencies of selected SNPs for CD patients and healthy controls.
Genotype

CD Patients (N = 54) Healthy Controls (N = 50) P-value* OR

95% CI

TNFα rs1800629
GG (Reference allele)

34 (64%)

41 (82%)

0.03

GA

20 (37%)

7 (14%)

0.01

3.6

1.37-9.54

AA

0 (0%)

2 (4%)

0.13

0.2

0.01-5.20

20 (37%)

9 (18%)

0.03

2.7

1.08-6.64

TT (Reference allele)

33 (61%)

34 (68%)

0.75

TC

18 (33%)

16 (32%)

0.89

1.2

0.51-2.64

CC

3 (6%)

0 (0%)

0.09

7.2

0.35-144.9

21 (39%)

16 (32%)

0.73

1.4

0.60-3.00

CC (Reference allele)

45 (83%)

43 (86%)

0.70

CT

9 (16%)

7 (14%)

0.38

1.2

0.42-3.59

TT

0 (0%)

0 (0%)

N/A

N/A

N/A

CT + TT

9 (16%)

7 (14%)

0.70

1.2

0.42-3.59

GA + AA
TNFα rs1799964

TC + CC
TNFα rs1799724

Genotype

CD Patients (N = 54) Healthy Controls (N = 50) P-value* OR

95% CI

TNFRSF1A rs4149584
CC (Reference allele)

52 (96%)

49 (98%)

0.60

CT

2 (4%)

1 (2%)

0.60

1.9

TT

0 (0%)

0 (0%)

N/A

N/A

CT + TT

2 (4%)

1 (0%)

0.60

1.9

0.17-21.40

AA (Reference allele)

17 (31%)

29 (58%)

0.01

AG

22 (41%)

19 (38%)

0.29

2.0

0.83-4.65

GG

15 (28%)

2 (4%)

0.01

9.2

1.98-42.83

AG + GG

37 (68%)

21 (42%)

0.01

3.0

1.34-6.71

GG (Reference allele)

25 (46%)

26 (52%)

0.56

GT

13 (24%)

18 (36%)

0.18

0.75

0.31-1.84

TT

16 (30%)

7 (14%)

0.06

2.4

0.83-6.75

GT + TT

29(54%)

25(50%)

0.70

1.2

0.56-2.59

0.17-21.40
N/A

TNFRSF1A rs767455

TNFRSF1A rs4149570

77

Genotype

CD Patients (N = 54) Healthy Controls (N = 50) P-value* OR

95% CI

TNFRSF1B rs1061624
AA (Reference allele)

13 (24%)

27 (54%)

0.01

AG

27 (50%)

15 (30%)

0.04

2.3

1.04-5.22

GG

14 (26%)

8 (16%)

0.02

3.6

1.21-10.83

AG + GG

41 (76%)

23 (46%)

0.01

3.7

1.61-8.53

TT (Reference allele)

24 (44%)

31 (62%)

0.07

TG

22 (41%)

16 (32%)

0.36

1.8

0.77-4.1

GG

8 (15%)

3 (6%)

0.14

3.44

0.82-14.4

TG + GG

30 (%)

19 (38%)

0.07

2.03

0.93-4.47

CC (Reference allele)

12 (22%)

31 (62%)

0.01

CT

31 (57%)

15 (30%)

0.01

3.1

1.4-7.07

TT

15 (28%)

4 (8%)

0.01

4.4

1.36-14.14

CT + TT

46 (85%)

19 (38%)

0.01

6.25

2.66-14.69

TNFRSF1B rs1061622

TNFRSF1B rs3397

Two-tailed Z test and odd ratio analysis were used to compare between the presence of SNPs in CD patients vs. healthy controls
*P-value of <0.05 was considered as significance threshold
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Table 6: Haplotypes inferred from TNFRSF1A rs767455 (A/G) - TNFRSF1B rs3397 (C/T)
and MAP infection distributions among CD patients.
Haplotype*

CD MAP (+)

CD MAP (-)

Overall

P-Value

(rs767455 - rs3397)

(N = 31)

(N = 23)

A-C

2 (4%)

6 (11%)

8 (15%)

0.14

G-C

3 (5%)

2 (4%)

5 (9%)

0.64

A-T

9 (17%)

7 (13%)

16 (30%)

0.59

G-T

17 (31%)

8 (15%)

25 (46%)

0.01

Fisher’s exact test was used to test group significance at P<0.05.
CD: Crohn’s Disease
MAP: Mycobacterium avium subspecies paratuberculosis
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CHAPTER FOUR: HIGHER POTENCY AND BROADER SPECTRUM OF
RHB-104 ANTI-MICROBIAL ACTIVITY IS OBSERVED IN ONE
CAPSULE FORMULATION FOR EFFECTIVE TREATMENT OF
CROHN’S DISEASE
Note: This chapter has been published in part and the citation link is:
Qasem, A., Safavikhasraghi, M., & Naser, S. A. (2016). A single capsule formulation of RHB104 demonstrates higher anti-microbial growth potency for effective treatment of Crohn’s
disease associated with Mycobacterium avium subspecies paratuberculosis. Gut pathogens, 8(1),
45.
Introduction
The current treatment guidelines of Crohn’s disease (CD) include immunosuppressants, antiinflammatory drugs, nutritional therapy and antibiotics [1]. MAP was isolated from intestinal
tissues, milk and blood samples from CD patients at a higher frequency than controls [2]. Other
microorganisms have been associated with CD such as L. monocytogenes, S. aureus, K.
pneumoniae and invasive E.coli [4]. CD patients treated with prolonged combination of
macrolide-based antimycobacterial regimens in randomized clinical trials have achieved reversal
of CD symptoms [5]. We have recently evaluated the effects of an investigational triple
antibiotics regimen known as RHB-104 (by RedHill Biopharma) against several clinical MAP
strains and other non-MAP mycobacterial strains in vitro [6]. Using BACTEC™ MGIT Para-TB
medium, based on fluorescence quenching technology, our data demonstrated that lower
concentrations of the triple combination of RHB-104 active ingredients provided synergistic
anti-MAP growth activity compared to individual or dual combinations of the drugs. RHB-104
active ingredients are composed of 63.3% Clarithromycin (CLA), 6.7% Clofazimine (CLO) and
30% Rifabutin (RIF). However, in our earlier study we were unable to dissolve the capsule
formulation in one compatible solution. Therefore, RHB-104 active ingredients solution was
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prepared at a final concentration of 1 mg/mL by combining the 3 individually dissolved drugs at
their respective percent composition in RHB-104.

Materials and Methods
RHB-104 active ingredients is composed of 63.3% Clarithromycin (CLA), 6.7% Clofazimine
(CLO) and 30% Rifabutin (RIF). In our earlier study [1], we were unable to dissolve the drug
formula in one compatible solution and therefore, RHB-104 active ingredients solution was
prepared at a final concentration of 1 mg/mL by combining the 3 individually dissolved drugs at
their respective percent composition in RHB-104. In this study, we successfully dissolved RHB104 formulation in one solution (due to propriety ownership, RHB-104 solvent information can
be requested directly from RedHill Biopharma). RHB-104 formulation solution was then
evaluated against MAP and several other microorganisms. Using same methodology, Minimum
inhibitory concentration (MIC) was determined for RHB-104 formulation and RHB-104 active
ingredients solution [1].

Results
In this study, we successfully dissolved RHB-104 formulation in one solution (due to propriety
ownership, RHB-104 solvent information can be requested directly from RedHill Biopharma).
RHB-104 formulation solution was then evaluated against MAP and several other
microorganisms. Using same methodology, Minimum inhibitory concentration (MIC) was
determined for RHB-104 formulation and RHB-104 active ingredients solution The dissolving
solution was tested against mycobacterial and other non-mycobacterial strains and it has shown
no inhibitory effect on their growth at concentration as high as 12.5% (V/V).
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The synergistic effects of RHB-104 capsule formula dissolved in one solution was more efficient
against mycobacterial strains than adding the three active ingredients individually to the culture
(Figure 15). This higher potency was observed against MAP strains and non-MAP mycobacteria
strains. RHB-104 capsule formula has shown bactericidal effect at 2 ug/ml MIC level against
MAP strain MS 137 isolated from intestinal tissues of CD patients, compared to 4ug/ml of active
ingredients added individually. Similarly, RHB-104 capsule formulation was bactericidal at
lower MIC level than combining individual active ingredients against M. avium JF7 isolated
from the blood of HIV patient, M. fortuitum subspecies fortuitum, M. smegmatis (ATCC 27199)
and M. tuberculosis strain HR237. The activity RHB-104 capsule formula against mycobacterial
strains in comparison to its individual active ingredients in details is shown in Table 7.
Additionally, we were interested to test the effect of RHB-104 against the other microbial
causative agents of CD. The drug was effective against S. aureus (ATCC 25923) and L.
monocytogenes (ATCC 19112) at MIC level of 0.125 and 0.25 ug/ml, respectively. Since CLA
composes about 63% of RHB-104 we tested it individually against those bacterial strains. The
MIC of CLA alone was 1.5 ug/ml for both S. aureus and L. monocytogenes. However, RHB-104
had no bactericidal effects against E. coli (ATCC 8739) and K. pneumonia (ATCC 13883) at
concentrations as high as 40ug/ml.

Conclusion
These additional data support our original study and confirms that RHB-104 should be effective
as a first-line treatment for CD associated with MAP, L. monocytogenes or S. aureus. This new
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regimen is given in one capsule formulation with lower concentration of 3 drugs instead of
giving them individually which increases patient’s compliance and minimizes side effects.

89

Figures

Figure 15: Comparing the bactericidal activity of RHB-104 capsule formulation to RHB104 active ingredients added individually against: MAP MS 137, M. smegmatis, L.
monocytogenes and S. aureus at MIC level.
*MIC level
**RHB-104 capsule formulation dissolved in one compatible solution (1mg/ml).
***RHB-104 active ingredients added into the culture individually; CLA was dissolved in a
solution made of sodium acetate in water (pH 5.0) at 1mg/ml, CLO (1mg/ml) was prepared
by using hydrochloric acid and sodium dodecyl sulfate in water, RIF (1mg/ml) was
prepared by using absolute ethanol.
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Tables

Table 7: MIC of the proprietary RHB-104 capsule formulation and RHB-104 analog
Microorganism

Minimum inhibitory concentration (μg/mL)
CLA-CLO-RIF (RHB-104
analog)a

Proprietary RHB-104
capsule formulationb

MAP MS 137

4.0

2.0

M. avium—JF7

4.0

2.0

M. fortuitum ss fortuitum

15

10

M. tuberculosis HR237

10

5.0

M. smegmatis ATCC 27199

6.0

0.125

S. aureus ATCC 25923

0.25

0.125

L. monocytogenes ATCC
19112

0.5

0.25

K. pneumonia ATCC 13883

>40

>40

Recombinant E. coli

>40

>40

All cultures were performed in duplicates and have been repeated three times.
a

RHB-104 analog where the 3 drugs dissolved individually were combined in one solution at
their proprietary RHB-104 capsule formulation composition percentage.
b

Proprietary RHB-104 capsule formulation was dissolved in one compatible solvent.
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CHAPTER FIVE: CONCLUSION/FUTURE DIRECTIONS
Numerous factors are involved in CD pathogenesis including microbial infection and genetic
susceptibility. We support the hypothesis that dysregulated immune response against MAP in
genetically susceptible individuals lead to disease development. However, current treatment
guidelines do not initially consider antimycobacterial therapy. Usually, therapy consists of antiinflammatories, immunomodulators and biologics, which may significantly impair macrophages
and formation of granulomas, which are essential for isolating and restricting microbial infection.
Therefore, an alternative combined therapy should be considered for long-term remission and
possibly a cure from this deleterious disease. Combining antibiotics in addition to targeted
immunotherapy is a better approach to block source and signs of inflammation.
Here, we identified the detrimental activity of recombinant TNFα, IL-6, IL-12, IL-23 and IFN-Ƴ
on MAP infection in vitro. Our data shows that anti-TNFα therapeutics do not have any direct
bactericidal effects against MAP or other non-mycobacterial strains at supratherapeutic
concentrations. However, these medications increased MAP survival in infected macrophages in
a concentration-dependent manner, indicating that CD patients receiving such treatment are at a
higher risk for MAP infection. On the other hand, MAP viability declined in infected
macrophages pulsed with exogenous rTNFα in a concentration-dependent manner, which shows
that TNFα plays a vital role in protection against MAP infection.
Furthermore, we found that gene expression level of TNFα, IL-6 and IL-12 are also increased
significantly in MAP or M. tuberculosis infected macrophages, which indicates that a high level
of these cytokines in CD patients could be a result of MAP infection. Interestingly, MAP
survival was increased significantly when exogenous rIL-6 was added to infected macrophages

in a concentration-dependent manner. However, rIL-23 and IFN-Ƴ had a similar effect to
rTNFα, where they reduced MAP viability significantly with higher concentrations.
There is a significant variable response among CD patients receiving anti-TNFα, where about
10-30% of IBD patients have no initial response to anti-TNFα treatment. However, Over 50% of
the anti-TNFα initial responders lose response to treatment over time. Additionally, genetic
polymorphisms in TNFRSF1A and TNFRSF1B have been shown to affect anti-TNFα treatment
response significantly among CD patients. Moreover, the risk for tuberculosis infection has
substantially increased in patients receiving anti-TNFα.
The SNPs TNFRSF1A:rs767455 and TNFRSF1B:rs3397 were both found to be associated with
decreased expression of their corresponding genes, while MAP infection susceptibility was
correlated with the SNPs TNFRSF1A:rs767455 and TNFRSF1B:rs3397. Our SNP haplotype
analysis of TNFRSF1A:rs767455 and TNFRSF1B:rs3397 points out that the G – T haplotype has
a significant difference in frequency among CD patients, and MAP infection is correlated with
this specific haplotype. Genetic testing for TNFRSF1A:rs767455 and TNFRSF1B:rs3397, in
addition to MAP infection screening should be implemented before anti-TNFα treatment
initiation in CD for more effective clinical outcome.
In the future, we would like to investigate the relationship between IL-6, Notch-1, STAT-3 and
MAP infection in CD. Cytokines are essential mediators linking inflammatory response in
various disease conditions. Since IL-6 was highly upregulated in MAP infected macrophages, it
could serve as a potential therapeutic target as well as a prognostic factor. Mainly, IL-6 plays a
significant role in inducing acute phase proteins such as C-reactive protein (CRP) [1]. Recently,
IL-6 was found to activate Th17 cells and Transforming Growth Factor (TGF-β) [2]. At the same
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time IL-6 was also found to be inhibiting T regulatory cells [3]. Thus, IL-6 promotes proinflammatory environment.
In CD, IL-6 induces T-cell resistance in the intestinal mucosa and it also induces endothelial
chemokines, which helps in recruiting more leukocytes [4]. The circulating levels of IL-6 in the
intestinal mucosa is a major risk factor for colon cancer development [5]. Patients with advanced
stage colorectal cancer have shown higher serum levels of IL-6 [6]. Although several studies
have identified that IL-6 can modulate inflammation, the underlying mechanism remains unclear
[7]. We are willing to focus on those mechanisms in our future studies and we would also like to
test the role of TNFα inhibitors on Notch-1, IL-6, apoptosis and MAP infection in vitro, in
addition to CD clinical samples.
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